In this pilot study, the in vitro antimicrobial activity of iclaprim, a diaminopyrimidine, tested in combination with other antimicrobials against recent and common Gram-positive and Gram-negative respiratory pathogens, was examined by the checkerboard method. The range of minimal inhibitory concentrations (MICs) for iclaprim against all bacteria tested in the study was 0.03 to >128 µg ml−1. Iclaprim exhibited synergy with sulfamethoxazole against 11 of the 16 bacterial strains tested, with mean fractional inhibitory concentration index (FICI) values of 0.2–0.5. Synergy with sulfamethoxazole was demonstrated against all Gram-positive bacteria and selected Gram-negative bacteria. Neither synergy nor antagonism was observed for combinations of iclaprim with ampicillin, meropenem, tetracycline, levofloxacin, aztreonam, piperacillin/tazobactam, colistin, cefepime or gentamicin against any of the bacterial strains tested. The significant reduction in the MIC values observed with the combination of iclaprim and sulfamethoxazole demonstrates that this regimen could be effective against common Gram-positive and selected Gram-negative respiratory bacteria.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SchneiderP, HawserS, IslamK. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett2003; 13:4217–4221 [View Article]
BryantAE, GomiS, KatahiraE, HuangDB, StevensDL. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. J Med Microbiol2019; 68:456–466 [View Article]
LaueH, WeissL, BernardiA, HawserS, LociuroS et al.In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother2007; 60:1391–1394 [View Article]
NovielloS, HawserS, SaderH, HuangDB. In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016. J Glob Antimicrob Resist2019; 16:236–238 [View Article]
AndrewsJ, HoneybourneD, AshbyJ, JevonsG, FraiseA et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother2007; 60:677–680 [View Article]
HuangDB, FileTM Jr, TorresA, ShorrAF, WilcoxMH et al. A phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous Iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to Gram-positive pathogens. Clin Ther2017; 39:1706–1718 [View Article]